BHWM
DNLI icon

Bay Harbor Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Bay Harbor Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180 Buy
7
+1
+17% +$21 ﹤0.01% 1190
2026
Q1 		$115 Buy
6
+3
+100% +$60 ﹤0.01% 1203
2025
Q4 		$49 Buy
3
+2
+200% +$34 ﹤0.01% 1269
2025
Q3 		$14 Hold
1
– – ﹤0.01% 1279
2025
Q2 		$13 Hold
1
– – ﹤0.01% 1261
2025
Q1 		$13 Buy
+1
New +$19 ﹤0.01% 1134

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bay Harbor Wealth Management's DNLI Position: Q2 2026 in Review

Bay Harbor Wealth Management increased its Denali Therapeutics (DNLI) stake by 17% in Q2 2026, buying an estimated $21 and bringing the position to 7 shares worth $180. The position accounts for ﹤0.01% of the portfolio, ranked #1190.

Bay Harbor Wealth Management first reported a position in DNLI in Q1 2025 and has held it in 6 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Bay Harbor Wealth Management held 7 shares of Denali Therapeutics worth $180 as of Q2 2026.
  • Bay Harbor Wealth Management bought 1 Denali Therapeutics share in Q2 2026, an estimated $21.
  • Denali Therapeutics made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #1190 holding.
  • Bay Harbor Wealth Management first reported a position in Denali Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.